Skip to content

Jianpi Qinghua approach for the treatment of chronic kidney failure: a multicenter, large sample prospective study

Jianpi Qinghua approach for the treatment of chronic kidney failure: a multicenter, large sample prospective study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003738
Enrollment
Unknown
Registered
2013-09-19
Start date
2013-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Jianpiqinghua formula & telmisartan placebo:Jianpiqinghua formula & telmisartan placebo
Telmisartan & jianpiqinghua formula placebo:Telmisartan & jianpiqinghua formula placebo
Jianpiqinghua formula & telmisartan:Telmisartan & jianpiqinghua formula

Sponsors

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. To be diagnosed as original chronic renal glomerular disease at CKD III stage, more than 70% were confirmed by histopathological examination of renal puncture; 3. 24h urinary protein excretion 0.5-2.0 grams; 4. At the begining and end of 2 weeks introducing period, GFR will be 30~59ml/min/1.73m2, 24h urinary protein excretion 0.5-2.0 grams, Bp=130/80 mmHg; 5. Has to be treated with two weeks wash-out duration for those patients used angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor antagonist (ARB) therapy; or those not used ACEI/ARB previously; 6. Non-dialysis patients whose risk factors such as infection, acidosis, electrolyte disorder, and hypertension, etc., have been controlled and with stable status, blood pressure 130-90/80-60mmHg and blood K+ concentration falls in normal range; 7. To be with TCM "spleen deficiency and damp-hot (Pixu Shire)" symptoms (zheng); 8. Accecpt protocol and signed informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe heart, brain, liver and blood system diseases; 2. Pregnancy or lactation period woman; 3. Patient with allergy reaction against the trial drug; 4. Patient is/was currently or in past three months involved in other clinical trial, or used glucocorticoids, immunosuppressants, Tripterygium preparations.

Design outcomes

Primary

MeasureTime frame
24h urinary protein excretion;urinary MA/Cr;serum creatitine;eGFR;blood urea nitrogen;serum albumin;

Countries

China

Contacts

Public ContactLiqun He

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Heliqun59@163.com+86 13501911124

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026